Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
News|Articles|April 30, 2026
Rational Off-Label Prescribing: A Review With Joseph F. Goldberg, MD, and Henry Nasrallah, MD, Part 2
Author(s)Joseph F. Goldberg, MD, Henry Nasrallah, MD
Clinicians explore neuroscience-guided off-label prescribing.
Advertisement
Advertisement
Joseph F. Goldberg, MD, sat down with Henry Nasrallah, MD, to discuss the essentials of off-label prescribing and uses of
Related to this article
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Advertisement
Advertisement